Taken together, these data along with other studies showing a modest effect of SGLT2 inhibitors on reducing NT‐proBNP and other circulating biomarkers associated with congestion, as well as a minimal long‐term diuretic effect, suggest that decongestion is not a predominant mechanism underlying the clinical benefits of SGLT2 inhibitors in HF.14, 15, 16, 17, 18. The gene discussed is NPPB; the disease is hydrops fetalis.